Topics:

Pre-IND Meeting for Lovaxin C

Pre-IND Meeting for Lovaxin C

NORTH BRUNSWICK, New Jersey—Advaxis, Inc. has conducted a pre-IND meeting with the FDA regarding its two planned phase II studies for its lead product Lovaxin C, a live Listeria vaccine for the treatment of cervical and head and neck cancers. The IND will be filed once phase I/II studies have been completed. In a separate news release, Advaxis announced that its breast cancer vaccine Lovaxin B, Listeria monocytogenes modified to deliver HER2/neu to immune cells, is in preclinical testing.

 
Loading comments...
Please Wait 20 seconds or click here to close